Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy. - Wikidata - awgldk - TriplyDB

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

http://www.wikidata.org/entity/Q34173419

about

Identifying patients at high risk of breast cancer recurrence: strategies to improve patient outcomes Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential Transfer RNA methytransferases and their corresponding modifications in budding yeast and humans: activities, predications, and potential roles in human health Garbage in, garbage out: a critical evaluation of strategies used for validation of immunohistochemical biomarkers Advances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine Clinical validation of the EndoPredict test in node-positive, chemotherapy-treated ER+/HER2- breast cancer patients: results from the GEICAM 9906 trial.Predictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.Association of survivin splice variants with prognosis and treatment of breast cancer.Time dependence of biomarkers: non-proportional effects of immunohistochemical panels predicting relapse risk in early breast cancer.BAI3, CDX2 and VIL1: a panel of three antibodies to distinguish small cell from large cell neuroendocrine lung carcinomas.Prediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.The Role of Proteomics in the Diagnosis and Treatment of Women's Cancers: Current Trends in Technology and Future Opportunities Combined comparative genomic hybridization and transcriptomic analyses of ovarian granulosa cell tumors point to novel candidate driver genes.Immunohistochemistry and mass spectrometry for highly multiplexed cellular molecular imaging.L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia.Transfer RNA detection by small RNA deep sequencing and disease association with myelodysplastic syndromes.Agreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX®) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancer.Breast cancer metastasis and the lymphatic system Mutation in WDR4 impairs tRNA m(7)G46 methylation and causes a distinct form of microcephalic primordial dwarfism Mining the Breast Cancer Proteome for Predictors of Drug Sensitivity.Signatures of tumor-immune interactions as biomarkers for breast cancer prognosis Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data.Posttranscriptional methylation of transfer and ribosomal RNA in stress response pathways, cell differentiation, and cancer Improving Pathological Assessment of Breast Cancer by Employing Array-Based Transcriptome Analysis.Molecular profiling for breast cancer: a comprehensive review.Breast Cancer Biomarkers: Utility in Clinical Practice.Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer.Adaptive designs for clinical trials assessing biomarker-guided treatment strategies.Hormonal therapy in breast cancer: a model disease for the personalization of cancer care.Clinical validity/utility, change in practice patterns, and economic implications of risk stratifiers to predict outcomes for early-stage breast cancer: a systematic review.Pathologic diagnosis, immunohistochemistry, multigene assays and breast cancer treatment: progress toward "precision" cancer therapy.Decision-making impact on adjuvant chemotherapy allocation in early node-negative breast cancer with a 21-gene assay: systematic review and meta-analysis.LAT1 is a putative therapeutic target in endometrioid endometrial carcinoma.Pathologic diagnosis of breast cancer patients: evolution of the traditional clinical-pathologic paradigm toward "precision" cancer therapy.A micro-RNA expression signature for human NAFLD progression Predicting clinical outcomes from large scale cancer genomic profiles with deep survival models.Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation.Twenty (forward looking) questions Clustering-Based Method for Developing a Genomic Copy Number Alteration Signature for Predicting the Metastatic Potential of Prostate Cancer.Personalized medicine in cancer: where are we today?

P2860

Q26778675-5E1D71E5-420D-4E25-A8A4-11626187E582 Q26782613-7A316988-A7C6-4A48-BD03-2B5083ACA445 Q26849751-CF450B16-6D3B-4E8D-8883-7258BB304D83 Q27001445-F1045AFF-F29A-4A4D-9AE6-2BD6FB1C00D4 Q27001994-B83B4857-973D-4981-8256-4AFA7A41572C Q33827057-4E9FC860-6BFE-4CAF-AA55-22AC02409621 Q34171119-D1C0C1AA-7160-4331-BCB9-3A64A13D4C45 Q34657717-2410AAF3-A573-47E1-9EC5-9CF30A4ADB2E Q34687019-3E4D5C8B-05CA-4115-BD80-65938079B94A Q35050907-9D4FAE80-B433-46DF-9CA7-64AF86CD737F Q35125648-D1088F90-05AD-48E4-A43B-15CBDD643B88 Q35185640-93F94F5A-EE94-4DDE-81FF-978721869457 Q35531774-EE4DAB98-50CD-45C5-90EB-A35DDBB394A1 Q35570005-45361F30-C81A-468E-9CBB-7167B38B4DB0 Q35757977-EBFDB3EE-51C3-4976-BC64-11019E915F45 Q35785942-912F02B4-B48D-4AA2-992D-1946DB733B7E Q35913234-78BF517E-7A7D-4AAC-AA6B-FB2EBF3F6470 Q35942984-99F5CA81-7CB2-490D-B754-04C9829F3497 Q36105008-5826BB25-346A-4D37-969F-71DDACDD6DB4 Q36210404-241C83DD-7928-44A9-BCE8-65142BD06AA7 Q36253304-F80C0923-DF9B-48A0-AD5C-0EEA23D31C3D Q36334258-D8A98A14-A75E-4C0A-AEF9-0138FBF3445B Q36722453-32FF2AA5-6737-4776-83D7-8747089DED2B Q37214212-0ED353B5-4C98-4289-A7CE-491DB8DE329C Q37302484-40858F7B-9E9E-493E-A0C9-CF4C88D50096 Q37441159-122F39FF-EC28-41FD-965C-593204032660 Q37495490-CD3D553B-A077-4481-BE7C-3B72FC91B739 Q37711677-FBE5A7DF-8710-4EDE-9FF8-4E3D45AA663D Q37992403-36056973-206D-4E01-AEC2-34116687200A Q38024305-E3005544-732F-42D3-BF95-0228351A1D15 Q38272730-DA6F6D3F-BA0A-4F28-B8A8-C9EAD03ABE46 Q38540963-4D01814A-64C8-4C02-8845-DEFCC67DB2A2 Q38754089-950B6B47-44CA-4DA4-9F61-907FD71B5286 Q39187437-D525B899-F486-469B-8EF6-540DAEA51941 Q41647903-866406CD-E18A-4262-B465-A270538199C9 Q41718329-51A07B05-6538-4DE4-9543-A053F51F430E Q42365301-BF981F8F-1672-488E-9D86-9D2510979D62 Q42833569-B49E3156-9E40-44E3-8B3B-1425333C0D88 Q43022331-9E017481-8CC0-4442-AF9D-973FCE3F5745 Q43828188-6287DE8D-0A20-44BA-A380-1F7BCC0F2D1E

P2860

Mammostrat as a tool to stratify breast cancer patients at risk of recurrence during endocrine therapy.

http://www.wikidata.org/entity/Q34173419

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Mammostrat as a tool to strati ...... ence during endocrine therapy.

@ast

Mammostrat as a tool to strati ...... ence during endocrine therapy.

@en

Mammostrat as a tool to strati ...... ence during endocrine therapy.

@nl

type

label

Mammostrat as a tool to strati ...... ence during endocrine therapy.

@ast

Mammostrat as a tool to strati ...... ence during endocrine therapy.

@en

Mammostrat as a tool to strati ...... ence during endocrine therapy.

@nl

prefLabel

Mammostrat as a tool to strati ...... ence during endocrine therapy.

@ast

Mammostrat as a tool to strati ...... ence during endocrine therapy.

@en

Mammostrat as a tool to strati ...... ence during endocrine therapy.

@nl

P1433

Q34173419-46C3B782-A60D-454F-8CAE-5C2B34B34AAA

P1476

Q34173419-74E3CFE4-3C21-4011-AA3B-63A9754ABCE1

P2093

Q34173419-19374AC6-23D8-4AB4-A071-C08FEC938A6A

Q34173419-20AD50A7-7F1F-4D45-AF8F-BFB692B7FC96

Q34173419-2F78D318-29A3-42F2-B104-145E8D16AD5D

Q34173419-30FEF330-8F8E-4E57-9E6B-037FB16F52F3

Q34173419-433911A7-2FBE-4529-ADC3-DE5AEE41A8BA

Q34173419-4D5ACE19-3B86-49E4-B51F-66148982AFE0

Q34173419-6232EC8C-86AF-413E-AD0C-F50A1A76C877

Q34173419-8774C601-308B-4C05-BFA7-9F5DCEF9639B

Q34173419-8956B776-7687-4B67-BCF9-951FAA9280A1

Q34173419-97FCB08E-34A0-489F-8E29-9A2A9DB49893

P2860

Q34173419-0DB657F1-29AC-4C8A-89F2-C3C1145DC5D3

Q34173419-0E6F6C62-99A9-4C56-91D4-276BDC3688BA

Q34173419-14FAE5D4-A781-406A-9D14-295AE870AC86

Q34173419-30020A3A-5353-4A7C-A8A9-3F671F7E1CB6

Q34173419-5628597D-B101-44A5-84BB-BD7DDB510A7B

Q34173419-5C18D563-600B-4340-B2B8-3D56BA12DA4F

Q34173419-69128A3A-AA72-4EC7-8916-CEAA7C769B40

Q34173419-6E5E41E2-F1D3-4BBA-B292-CA641BA45895

Q34173419-820597F3-2EE4-4C21-8017-6830B428E440

Q34173419-84D3D8F8-E71C-4529-911F-9AFC977CF1F4

P2888

Q34173419-97EF8C1B-5B0C-46CC-96A6-B328D5EC59F9

P304

Q34173419-9FF2878B-F095-4CA4-904F-67B550EEF4DE

P31

Q34173419-8900E51F-3729-4060-9960-D48D1FD25547

P356

Q34173419-24C40AD4-693E-4597-A580-6596B832EE99

P433

Q34173419-C7DC957D-0E3B-4387-AFBE-CC6AF074E333

P478

Q34173419-3524E048-4985-4496-A2D5-B758C149DC2B

P50

Q34173419-4A0F9F38-396E-491E-8F8D-374FFE896F4F

P577

Q34173419-58201CE1-5AAF-4E7A-AB10-9C8E79C84CB2

P5875

Q34173419-FA3BB327-AC61-4D03-9F4D-E0C0F6FEBCE8

P6179

Q34173419-8C7D1891-BC3F-425C-9EE2-24DCA7B2E556

P698

Q34173419-DEA1C3A3-DF1F-4D54-85CA-3617B8D05293

P932

Q34173419-94B3F8FD-9B52-4CCD-899B-FFBAD8C88F7C

P356

P1433

Breast Cancer Research

P1476

Mammostrat as a tool to strati ...... ence during endocrine therapy.

@en

P2093

Alison Munro

http://www.w3.org/2001/XMLSchema#string

Brian Z Ring

http://www.w3.org/2001/XMLSchema#string

David A Cameron

http://www.w3.org/2001/XMLSchema#string

Fiona M Campbell

http://www.w3.org/2001/XMLSchema#string

Gillian R Kerr

http://www.w3.org/2001/XMLSchema#string

Hans Christian Pedersen

http://www.w3.org/2001/XMLSchema#string

Ian H Kunkler

http://www.w3.org/2001/XMLSchema#string

Jeremy Thomas

http://www.w3.org/2001/XMLSchema#string

John M S Bartlett

http://www.w3.org/2001/XMLSchema#string

Laura Johnstone

http://www.w3.org/2001/XMLSchema#string

P2860

Gene expression profiling predicts clinical outcome of breast cancer

Molecular portraits of human breast tumours

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis

Pathological prognostic factors in breast cancer.

Up-front use of aromatase inhibitors as adjuvant therapy for breast cancer: the emperor has no clothes.

Chemosensitivity and stratification by a five monoclonal antibody immunohistochemistry test in the NSABP B14 and B20 trials.

Tamoxifen: the drug that came in from the cold.

External quality assurance of HER2 FISH and ISH testing: three years of the UK national external quality assurance scheme.

P2888

P304

R47

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/BCR2604

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

12

http://www.w3.org/2001/XMLSchema#string

P50

Douglas T. Ross

P577

2010-07-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

45112787

http://www.w3.org/2001/XMLSchema#string

P6179

1053691131

http://www.w3.org/2001/XMLSchema#string

P698

20615243

http://www.w3.org/2001/XMLSchema#string

P932

2949634

http://www.w3.org/2001/XMLSchema#string